Journal article

The median informs the message: Accuracy of individualized scenarios for survival time based on oncologists' estimates

BE Kiely, AJ Martin, MHN Tattersall, AK Nowak, D Goldstein, NRC Wilcken, DK Wyld, EA Abdi, A Glasgow, PJ Beale, M Jefford, PA Glare, MR Stockler

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2013

Abstract

Purpose: To determine the accuracy and usefulness of oncologists' estimates of survival time in individual patients with advanced cancer. Patients and Methods: Twenty-one oncologists estimated the "median survival of a group of identical patients" for each of 114 patients with advanced cancer. Accuracy was defined by the proportions of patients with an observed survival time bounded by prespecified multiples of their estimated survival time. We expected 50% to live longer (or shorter) than their oncologist's estimate (calibration), 50% to live from half to double their estimate (typical scenario), 5% to 10% to live ≤ one quarter of their estimate (worst-case scenario), and 5% to 10% to live ..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

B.E.K. was supported by a National Breast Cancer Foundation PhD Scholarship, a Cancer Institute NSW Research Scholar Award, and a National Health and Medical Research Council (NHMRC) Australia Program Grant. The ZEST Trial was supported by grants from the Cancer Councils of New South Wales and South Australia, the NHMRC of Australia, Pfizer Australia, Pfizer International, and the Clinical Trials Partnership of the Cancer Institute New South Wales and the NHMRC Clinical Trials Centre.